
Topic
Generics
ANDA strategy, Paragraph IV risk, therapeutic equivalence, supply concentration, and price erosion.

Generics· June 24, 2026 · 18 min read
By Ran Chen#Orange Book#Generics#Generic Entry

Generics· June 22, 2026 · 19 min read
Generic Lanreotide Acetate: 505(b)(2) Approvals and Medical-Benefit Coding
By Ran Chen#Generics#FDA Approval#Orange Book

Generics· June 22, 2026 · 19 min read
Generic Vyvanse (Lisdexamfetamine): Shortage Status, API Quotas, and NADAC Price Erosion
By Ran Chen#Generics#Drug Pricing#Supply Chain

Generics· June 21, 2026 · 5 min read
Generic Contrast Media: Amneal's Iohexol CGT Exclusivity and Shortage Triage
By Ran Chen#Generics#Orange Book#Manufacturing Capacity

Generics· June 21, 2026 · 10 min read
Generic Sandostatin LAR Depot: CGT Exclusivity, Supply Shocks, and Buy-and-Bill Economics
By Ran Chen#Generics#Orange Book#HCPCS Coding

Generics· June 13, 2026 · 17 min read
Orange Book TE codes: how to tell whether a generic can actually be substituted
By Ran Chen#Orange Book#ANDA Approval#Generics

Generics· May 27, 2026 · 12 min read
Hatch-Waxman 180-day exclusivity forfeiture guide
By Ran Chen#Generics#ANDA Approval#Orange Book

Approvals· May 10, 2026 · 4 min read
Orange Book vs Purple Book: the launch-team read that prevents bad assumptions
By Ran Chen#Orange Book#Purple Book#FDA Approval

Generics· May 6, 2026 · 3 min read
Generic entry, ANDA, and 505(b)(2): the commercial difference
By Ran Chen#Generics#505(b)(2)#Orange Book